Clinical trials in Castelo Branco

Clinical research in Castelo Branco is concentrating on immune system diseases, specifically allergic rhinoconjunctivitis with or without asthma triggered by grass and olive pollen. The studies evaluate the therapeutic benefit of allergen immunotherapy using a mobile symptom‑medication score to compare active treatment against placebo.

• Grass and olive allergen immunotherapy administered over multiple injections
• Use of a mobile application to capture combined symptom and medication scores
• Placebo‑controlled, double‑blind design to assess clinical efficacy
• Evaluation of treatment impact during peak pollen seasons

Findings aim to confirm that targeted immunotherapy can reduce allergy burden and improve quality of life for patients with seasonal respiratory allergies.

The respiratory tract diseases portfolio in Castelo Branco focuses on allergic rhinitis and controlled asthma associated with grass pollen exposure. Trials measure how allergen immunotherapy modifies airway reactivity and medication use, employing both double‑blind and open‑label phases to capture comprehensive efficacy data.

• Assessment of clinical efficacy of grass allergen immunotherapy across concentrations
• Change in allergen dose required for a positive challenge test after treatment
• Combined symptom‑medication score collected via mobile app during pollen peaks
• Comparison of active therapy with placebo to determine treatment benefit

The goal is to demonstrate that immunotherapy can sustainably lessen respiratory symptoms and reduce reliance on rescue medication for individuals with seasonal allergies.